Interferon-α therapy in bcr-abl-negative myeloproliferative neoplasms

Leukemia

Volumn 22, Issue 11, 2008, Pages 1990-1998

  Kiladjian, J J ^a,b,c   Chomienne, C ^b   Fenaux, P ^a  

^a AVICENNE HOSPITAL   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ALPHA INTERFERON; ALPHA INTERFERON RECEPTOR; ALPHA2 INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; BCR ABL PROTEIN; BETA INTERFERON; BETA1A INTERFERON; GAMMA INTERFERON; HORMONE; HYDROXYUREA; INTERFERON BETA SERINE; JANUS KINASE; JANUS KINASE 2; MACROGOL; PARACETAMOL; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PHOSPHORUS; RECOMBINANT ERYTHROPOIETIN;

ACUTE LEUKEMIA; ANEMIA; ANXIETY; ARTHRALGIA; AUTOIMMUNE DISEASE; BACKACHE; BLOOD TOXICITY; CARDIOTOXICITY; CHILL; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FATIGUE; FLU LIKE SYNDROME; FOLLICULAR LYMPHOMA; GASTROINTESTINAL TOXICITY; GLOMERULONEPHRITIS; HAIR LOSS; HAIRY CELL LEUKEMIA; HEMOLYSIS; HORMONE SUBSTITUTION; HUMAN; HYPEREOSINOPHILIC SYNDROME; HYPOTHYROIDISM; INJECTION SITE REACTION; IRRITABILITY; LEUKEMIA REMISSION; LIVER TOXICITY; LYMPHOCYTOPENIA; MALAISE; MENTAL INSTABILITY; MONOTHERAPY; MOOD CHANGE; MUSCULOSKELETAL PAIN; MYALGIA; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; NAUSEA; NEUROTOXICITY; NEUTROPENIA; POLYARTHRITIS; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN TOXICITY; SPLENOMEGALY; SYSTEMIC MASTOCYTOSIS; THROMBOCYTOPENIA; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; THYROIDITIS; URTICARIA; WEIGHT REDUCTION;

EID: 56249104095     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.280     Document Type: Review

References (99)

1. Isaacs A, Lindemann J. Virus interference.I. The interferon. Proc R Soc Lond B Biol Sci 1957; 147: 258-267.
2. Pestka S, Krause CD, Walter MR. Interferons, interfeton-like cytokines, and their receptors. Immunol Rev 2004; 202: 8-32.
3. Krause CD, Pestka S. Evolution of the Class 2 cytokines and receptors, and discovery of new friends and relatives. Pharmacol Ther 2005; 106: 299-346.
4. Cantell K, Hirvonen S, Kauppinen HL, Myllyla G. Production of interferon in human leukocytes from normal donors with the use of Sendai virus. Methods Enzymol 1981; 78 (Part A): 29-38.
5. Derynck R, Content J, DeClercq E, Volckaert G, Tavernier J, Devos R et al. Isolation and structure of a human fibroblast interferon gene. Nature 1980; 285: 542-547.
6. Maeda S, McCandliss R, Gross M, Sloma A, Familletti PC, Tabor JM et al. Construction and identification of bacterial plasmids containing nucleotide sequence for human leukocyte interferon. Proc Natl Acad Sci USA 1980; 77: 7010-7013.
7. Nagata S, Taira H, Hall A, Johnsrud L, Streuli M, Ecsodi J et al. Synthesis in E. coli of a polypeptide with human leukocyte interferon activity. Nature 1980; 284: 316-320.
8. Pestka S. The interferons: 50 years after their discovery, there is much more to learn. J Biol Chem 2007; 282: 20047-20051.
9. de Weerd NA, Samarajiwa SA, Hertzog PJ. Type I interferon receptors: biochemistry and biological functions. J Biol Chem 2007; 282 20053-20057.
10. Krause CD, Mei E, Xie J, Jia Y, Bopp MA, Hochstrasser RM et al. Seeing the light: Preassembly and ligand-induced changes of the interferon gamma receptor complex in cells. Mol Cell Proteomics 2002; 1: 805-815.
11. Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 2005; 5: 375-386.
12. Tough DF, Sun S, Zhang X, Sprent J. Stimulation of naive and memory T cells by cytokines. Immunol Rev 1999; 170: 39-47.
13. Ortaldo JR, Mason A, Rehberg E, Moschera J, Kelder B, Pestka S et al Effects of recombinant and hybrid recombinant human leukocyte interferons on cytotoxic activity of natural killer cells. J Biol Chem 1983; 258: 15011-15015.
14. Greiner JW, Guadagni F, Noguchi P, Pestka S, Colcher D, Fisher PB et al. Recombinant interferon enhances monoclonal antibody-targeting of carcinoma lesions in vivo. Science 1987; 235: 895-898.
15. Carlo-Stella C, Cazzola M, Gasner A, Barosi G, Dezza L, Meloni F et al. Effects of recombinant alpha and gamma interferons on the in vitro growth of circulating hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM) from patients with myelofibrosis with myeloid metaplasia. Blood 1987; 70: 1014-1019.
16. Castello G, Lerza R, Cerruti A, Cavallini D, Bogliolo G, Pannacciulli I. The in vitro and in vivo effect of recombinant interferon alpha-2a on circulating haemopoietic progenitors in polycythaemia vera. Br J Haematol 1994; 87: 621-623.
17. Dudley JM, Westwood N, Leonard S, Eridani S, Pearson TC. Primary polycythaemia: Positive diagnosis using the differential response of primitive and mature erythroid progenitors to erythropoletin, interleukin 3 and alpha-interferon. Br J Haematol 1990; 75: 188-194.
18. Hino M, Futami E, Okuno S, Miki T. Nishizawa Y. Morii H. Possible selective effects of interferon alpha-2b on a malignant clone in a case of polycythemia vera. Ann Hematol 1993; 66: 161-162.
19. Liu E, Jelinek J, Pastore YD, Guan Y, Prchal JF, Prchal JT. Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin. Blood 2003; 101: 3294-3301.
20. Massaro P, Foa P, Pomati M, LaTargia ML, Iurlo A, Clerici C et al. Polycythemia vera treated with recombinant interferon-alpha 2a: Evidence of a selective effect on the malignant clone. Am J Hematol 1997; 56: 126-128.
21. Messora C, Bensi L, Vecchi A, Longo R, Giacobbi F, Temperani P et al Cytogenetic conversion in a case of polycythaemia vera treated with interferon-alpha, Br J Haematol 1994; 86: 402-404.
22. Kiladjian JJ, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M et al. Pegylated Interferon-alfa-2a induces complete hematological and molecular responses with low toxicity in Polycythemia Vera. Blood 2008; PMID:18650451 [e-pub ahead of print].
23. Kiladjian JJ, Cassinat B, Turlure P, Cambier N, Roussel M, Bellucci S et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood 2006; 108: 2037-2040.
24. Chott A, Gisslinger H, Thiele J, Fritz E, Linkesch W, Radaszkiewicz T et al. Interferon-alpha-induced morphological changes of megakaryocytes: A histomorphometrical study on bone marrow biopsies in chronic myeloproliferative disorders with excessive thrombocytosis. Br J Haematol 1990; 74: 10-16.
25. Wang Q, Miyakawa Y, Fox N, Kaushansky K. Interferon-alpha directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1. Blood 2000; 96: 2093-2099.
26. Silver RT. Recombinant interferon-alpha for treatment of polycythaemia vera. Lancet 1988; 2: 403.
27. Bellucci S, Harousseau JL, Brice P, Tobelem G. Treatment of essential thrombocythaemia by alpha 2a interferon. Lancet 1988; 2: 960-961.
28. Giles FJ, Singer CR, Gray AG, Yong KL, Brozovic M, Davies SC et al Alpha-interferon therapy for essential thrombocythaemia. Lancet 1988; 2: 70-72.
29. Cacciola E, Giustolisi R, Guglielmo P, Di Raimondo F, Calogero RD. Recombinant interferon alpha in the treatment of polycythemia vera. Blood 1991; 77: 2790-2791.
30. Cimino R, Rametta V, Matera C, Mele G, Mettivier V, Ferrara F. Recombinant interferon alpha-2b in the treatment of polycythemia vera. Am J Hematol 1993; 4: 155-157.
31. Finelli C, Gugliotta L, Gamberi B, Vianelli N, Visani G, Tura S. Relief of intractable pruritus in polycythemia vera with recombinant interferon alfa. Am J Hematol 1993; 43: 316-318.
32. Turri D, Mitra ME, Di Trapani R, Lipari MG, Perricone R, Cajozzo A. Alpha-interferon in polycythemia vera and essential thrombocythemia. Haematologica 1991; 76: 75-77.
33. Papineschi F, Bucalossi A, Capochiani E, Benedetti E, Bramanti E, Dastoli G et al. Recombinant alpha 2a interferon and polycythemia vera: Clinical results and biological evaluation by means of Fourier-transform infrared microspectroscopy. Eur J Haematol 1994; 53: 213-217.
34. Sacchi S, Leoni P, Liberati M, Riccardi A, Tabilio A, Tartoni P et al A prospective comparison between treatment with phlebotomy alone and with interferon-alpha in patients with polycythemia vera. Ann Hematol 1994; 68: 247-250.
35. Muller EW, de Wolf JT, Egger R, Wijermans PW, Huijgens PC, Halie MR et al. Long-term treatment with interferon-alpha 2b for severe pruritus in patients with polycythaemia vera. Br J Haematol 1995; 89: 313-318.
36. Taylor PC, Dolan G, Ng JP, Paul B, Collin R, Reilly JT. Efficacy of recombinant interferon-alpha (rIFN-alpha) in polycythaemia vera: A study of 17 patients and an analysis of published data. Br J Haematol 1996; 92: 55-59.
37. Foa P, Massaro P, Caldiera S, LaTargia ML, lurlo A, Clerici C et al Long-term therapeutic efficacy and toxicity of recombinant interferon-alpha 2a in polycythaemia vera. Eur J Haematol 1998; 60: 273-277.
38. Gilbert HS. Long term treatment of myeloproliferative disease with interferon-alpha-2b: Feasibility and efficacy. Cancer 1998; 83 1205-1213.
39. Stasi R, Venditti A, Del Poeta G, Conforti M, Brunetti M, Bussa S et al. Role of human leukocyte interferon-alpha in the treatment of patients with polycythemia vera. Am J Med Sci 1998; 315: 237-241.
40. Heis N, Rintelen C, Gisslinger B, Knobl P, Lechner K, Gisslinger H. The effect of interferon alpha on myeloproliferation and vascular; complication polycytherma vera. Eur J Haematol 1999; 62: 27-31.
41. Radin AI, Kim HT, Grant BW, Bennett. JM, Kirkwood JM, Stewart JA et al. Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): A trial of the Eastern Cooperative-Oncology Group. Cancer 2003; 98: 100-109.
42. Silver RT. Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha: Cancer 2006; 107: 451-458.
43. Samuelsson J, Hasselbalch H, Bruserud O, Temerinac S, Brandberg Y,. Merup M et al. A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life. Cancer 2006; 106: 2397-2405.
44. Gugliotta L, Bagnara GP, Catani L, Gaggioli L, Guarini A, Zauli G et al. In vivo and in vitro inhibitory effect of alpha-interferon on megakaryocyte colony growth in essential thrombocythaemia. Br J Haematol 1989; 71: 177-181.
45. Lazzarino M, Vitale A, Morra E, Gagliardi A, Bernasconi P, Torromeo C et al. Interferon alpha-2b as treatment for Philadelphia-negative chronic myeloproliferative disorders with excessive thrombocytosis. Br J Haematol 1989; 72: 173-177.
46. Giralt M, Rubio D, Cortes MT, San Miguel J, Steegmann JL, Serena J et al. alpha Interferon in the management of essential thrombocythaemia. Eur J Cancer 1991; 27 (Suppl 4): S72-S74.
47. Gisslinger H, Chott A, Scheithauer W, Gilly B, Linkesch W, Ludwig H. Interferon in essential thrombocythaemia. Br J Haematol 1991; 79 (Suppl 1): 42-47.
48. Sacchi S, Tabilio A, Leoni P, Riccardi A, Vecchi A, Messora C et al Interferon alpha-2b in the long-term treatment of essential thrombocythemia. Ann Hematol 1991; 63: 206-209.
49. Seewann HL, Zikulnig R, Gallhofer G, Schmid C. Treatment of thrombocytosis in chronic myeloproliferative disorders with interferon alfa-2b. Eur J Cancer 1991; 27 (Suppl 4): S58-S62; discussion S62-53.
50. Kasparu H, Bernhart M, Krieger O, Lutz D. Remission may continue after termination of rIFN alpha-2b treatment for essential thrombocythemia. Eur J Haematol 1992; 48: 33-36.
51. Rametta V, Ferrara F, Marottoli V, Matera C, Mettivier V, Cimino R. Recombinant interferon alpha-2b as treatment of essential thrombocythaemia. Acta Haematol 1994; 91: 126-129.
52. Berte R, Villisa D, Ferrari B, Civardi G, Sbolli G, Cavanna L. Low-dose interferon alpha treatment in essential thrombocythemia. Eur J Haematol 1996; 56: 104-105.
53. Sacchi S, Gugliotta L, Papineschi F, Liberati AM, Rupoli S, Delfini C et al. Alfa-interferon in the treatment of essential thrombocythemia: clinical results and evaluation of its biological effects on the hematopoietic neoplastic clone. Italian Cooperative Group on ET. Leukemia 1998; 12: 289-294.
54. Alvarado Y, Cortes J, Verstovsek S, Thomas D, Faderl S, Estrov Z et al. Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia. Cancer Chemother Pharmacol 2003; 51 81-86.
55. Saba R, Jabbour E, Giles F, Cortes J, Talpaz M, O'Brien S et al. Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986. Cancer 2005; 103: 2551-2557.
56. Langer C, Lengfelder E, Thiele J, Kvasnicka HM, Pahl HL, Beneke H et al. Pegylated interferon for the treatment of high risk essential thrombocythemia: Results of a phase II study. Haematologica 2005; 90: 1333-1338.
57. Jabbour E, Kantarjian H, Cortes J, Thomas D, Garcia-Manero G, Ferrajoli A et al. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: Final result of a phase 2 study. Cancer 2007; 110: 2012-2018.
58. Tefferi A, Elliot MA, Yoon SY, Li CY, Mesa RA, Call TG et al. Clinical and bone marrow effects of interferon alfa therapy in myelofibrosis with myeloid metaplasia. Blood 2001; 97: 1896.
59. Heis-Vahidi-Fard N, Forberg E, Eichinger S, Chott A, Lechner K, Gisslinger H. Ineffectiveness of interferon-gamma in the treatment of idiopathic myelofibrosis: A pilot study. Ann Hematol 2001; 80 79-82.
60. Kozlowski A, Charles SA, Harris JM. Development of pegylated interferons for the treatment of chronic hepatitis C. BioDrugs 2001; 15: 419-429.
61. Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK et al Pegylated interferon-alpha2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 2000; 68: 556-567.
62. Michallet M, Maloisel F, Delain M, Hellmann A, Rosas A, Silver RT et al. Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: A phase III study. Leukemia 2004; 18: 309-315.
63. Barosi G, Bordessoule D, Briere J, Cervantes F, Demory JL, Dupriez B et al. Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET). Blood 2005; 106: 2849-2853.
64. Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg HJ, Reilly JT et al International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006; 108 1497-1503.
65. Sacchi S, Kantarjian H, O'Brien S, Cohen PR, Pierce S, Talpaz M. immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J Clin Concol 1995; 13, 2401-2407.
66. Steegmann JL, Requena MJ, Martin-Regueira P, De La Camara R, Casado F, Salvanes FR et al. High incidence of autoimmune alterations in chronic myeloid leukemia patients treated with interferon-alpha. Am J Hematol 2003; 72: 170-176.
67. Wandl UB, Nagel-Hiemke M, May D, Kreuzfelder E, Kloke O, Kranzhoff M et al. Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders. Clin Immunol Immunopathol 1992; 65: 70-74.
68. Zuffa E, Vianelli N, Martinelli G, Tazzari P, Cavo M, Tura S. Autoimmune mediated thrombocytopenia associated with the use of interferon-alpha in chronic myeloid leukemia. Haematologica 1996; 81: 533-535.
69. Treatment of polycythaemia vera by radiophosphorus or busulphan: A randomized trial. 'Leukemia and Hematosarcoma' Cooperative Group, European Organization for Research on Treatment of Cancer (E.O.R.T.C.) Br J Cancer 1981; 44: 75-80.
70. Berk PD, Wasserman L, Fruchtman S, Goldberg JT. Treatment of polycythaemia vera, a summary of clinical trends conducted by the polycythaemia vera sub-group. In: Wasserman L, Berk PD (eds). Treatment of Polycythaemia Vera, a Summary of Clinical Trends Conducted by the Polycythaemia Vera Study Group. W.B. Saunders: Philadelphia, PA, 1995, pp 166-194.
71. Najean Y, Rain JD. Treatment of polycythemia vera: The use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood 1997; 90: 3370-3377.
72. Najean Y, Rain JD. Treatment of polycythemia vera: Use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group. Blood 1997; 89: 2319-2327.
73. Finazzi G, Caruso V, Marchioli R, Capnist G, Chisesi T, Finelli C et al. Acute leukemia in polycythemia vera: An analysis of 1638 patients enrolled in a prospective observational study. Blood 2005; 105 2664-2670.
74. Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: A final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 1997; 34: 29-39.
75. Sterkers Y, Preudhomme C, Lai JL, Demory JL, Caulier MT, Wattel E et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: High proportion of cases with 17p deletion. Blood 1998; 91: 616-622.
76. Gangat N, Strand J, Li CY, Wu W, Pardanani A, Tefferi A. Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol 2007; 138: 354-358.
77. Gangat N, Wolanskyj AP, McClure RF, Li CY, Schwager S, Wu W et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: A single institutional study of 605 patients. Leukemia 2007; 21: 270-276.
78. Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004; 117: 755-761.
79. Lanzkron S, Strouse JJ, Wilson R, Beach MC, Haywood C, Park H et al Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease. Ann Intern Med 2008; 148: 939-955.
80. Kiladjian JJ, Rain JD, Bernard JF, Briere J, Chomienne C, Fenaux P. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost 2006; 32 (4 Part 2): 417-421.
81. Barbui T, Barosi G, Grossi A, Gugliotta L, Liberato LN, Marchetti M et al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2004; 89: 215-232.
82. McMullin MF, Bareford D, Campbell P, Green AR, Harrison C, Hunt B et al. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol 2005; 130: 174-195.
83. Pardanani A. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia 2008; 22: 23-30.
84. Lengfelder E, Berger U, Hehlmann R. Interferon alpha in the treatment of polycythemia vera. Ann Hematol 2000; 79: 103-109.
85. Lengfelder E, Griesshammer M, Hehlmann R. Interferon-alpha in the treatment of essential thrombocythemia. Leuk Lymphoma 1996; 22 (Suppl 1): 135-142.
86. Kiladjian JJ, Elkassar N, Cassinat B, Hetet G, Giraudier S, Balitrand N et al. Essential thrombocythemias without V617F JAK2 mutation are clonal hematopoietic stem cell disorders. Leukemia 2006; 20: 1181-1183.
87. Kralovics R, Teo SS, Li S, Theocharides A, Buser AS, Tichelli A et al Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood 2006; 108: 1377-1380.
88. Nussenzveig RH, Swierczek SI, Jelinek J, Gaikwad A, Liu E, Verstovsek S et al. Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol 2007; 35: 32-38.
89. Rumi E, Passamonti F, Pietra D, Della Porta MG, Arcaini L, Boggi et al. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. Cancer 2006; 107: 2206-2211.
90. Passamonti F, Rumi E, Pietra D, Della Porta MG, Boveri E, Pascutto C et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood 2006; 107: 3676-3682.
91. Vannucchi AM, Antonioli E, Guglielmelli P, Longo G, Pancrazzi A, Ponziani V et al. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 2007; 21: 1952-1959.
92. Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol 2005; 33: 523-530.
93. Falanga A, Marchetti M, Vignoli A, Balducci D, Russo L, Guerini V et al. V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. Exp Hematol 2007; 35: 702-711.
94. Girodon F, Schaeffer C, Cleyrat C, Mounier M, Lafont I, Dos Santos F et al. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy. Haematologica 2008; PMID:18728027 [e-pub ahead of print].
95. Ricksten A, Palmqvist L, Johansson P, Andreasson B. Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia. Haematologica 2008; 93: 1260-1261.
96. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT et al Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: A prospective study. Lancet 2005; 366: 1945-1953.
97. Sirhan S, Lasho TL, Hanson CA, Mesa RA, Pardanani A, Tefferi A. The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea. Am J Hematol 2008; 83: 363-365.
98. Griesshammer M, Struve S, Harrison CM. Essential thrombocythemia/ polycythemia vera and pregnancy: The need for an observational study in Europe. Semin Thromb Hemost 2006; 32 (4 Part 2): 422-429.
99. Harrison C. Pregnancy and its management in the Philadelphia negative myeloproliferative diseases. Br J Haematol 2005; 129: 293-306.